[Comment] Gepotidacin shows promise for the treatment of uncomplicated gonorrhoea

Gonorrhoea, a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, remains a major public health threat globally. In 2020, WHO estimated 82·4 million new global gonorrhoea cases among people aged 15–49 years old,1 and the prevalence remains high in many low-income and middle-income countries and increasing in many high-income countries.2,3 It can be transmitted through unprotected vaginal, oral, or anal intercourse, and from infected mothers to neonates during delivery. Most men with gonococcal urethritis are symptomatic, but at least half of women with cervicitis are asymptomatic.